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Mechanical ventilationAbstract Acute exacerbation of COPD (AECOPD) is an important but occasionally overlooked
parameter. COPD exacerbations are very common, affecting about 20% of COPD patients. The
bacterial infection plays an important role in the exacerbation of COPD patients. Quick and accu-
rate recognition of these patients along with aggressive and prompt intervention may be the only
action that prevents frank respiratory failure.
Aim of the work: The aim of this work is to clarify the role of serum procalcitonin in predicting
the bacterial exacerbations of COPD patients and their needs for mechanical ventilation.
Methods: 30 COPD patients with bacterial exacerbations, 23 stable COPD patients and 20
healthy control subjects of similar age and sex were included in the study. PCT levels in the serum
samples were measured in all subjects.
Results: There was a highly statistically signiﬁcant difference (p value <0.001) between
AECOPD patients (1.44 ± 0.542 ng/ml) on one side and stable COPD patients
(0.05 ± 0.012 ng/ml) and healthy control subjects (0.04 ± 010 ng/ml) on the other side regarding
the mean values of PCT. Also, we found a statistically signiﬁcant difference (p value <0.05)
between AECOPD patients infected with Pseudomonas aeruginosa and AECOPD patients infected
with other bacteria regarding the mean serum levels of PCT. A statistically signiﬁcant difference (p
value <0.001) was present among AECOPD patients that needed ventilatory support
(2.024 ± 0.564 ng/ml) and those did not need mechanical ventilation (1.262 ± 0.399 ng/ml). We
detected a highly statistically positive correlation (p value <0.001) between PCT serum levels,
CRP (r= 0.662) and WBC count (r= 0.591). Also, we found a highly statistically negative
correlation (p< 0.05) between PCT serum levels and FEV1 (r= 0.625).
Conclusions: This study found increased PCT serum levels among AECOPD patients and sug-
gests a role for PCT in the predicting of the bacterial exacerbations and their needs for ventilatory
support. We recommend other large studies to augment our ﬁndings.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
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Chronic obstructive pulmonary disease (COPD) is a major
public health problem. It is the fourth leading cause of chronic
morbidity and mortality in the United States, and is projected
to rank ﬁfth in 2020 in burden of disease caused worldwide,
according to a study published by the World Bank/World
Health Organization [1].
Patients with COPD are susceptible to many insults that
can lead rapidly to an acute deterioration superimposed on
chronic disease. Acute exacerbation of COPD (AECOPD) is
an important but occasionally overlooked parameter. COPD
exacerbations are very common, affecting about 20% of
patients with moderate-to-severe COPD (1.3 events per year
in patients with 40–45% predicted FEV1). The bacterial infec-
tion plays an important role in the exacerbation of COPD
patients. Quick and accurate recognition of these patients
along with aggressive and prompt intervention may be the only
action that prevents frank respiratory failure [2].
Procalcitonin (PCT) is a peptide precursor of hormone cal-
citonin, the later being involved with calcium homeostasis. It is
composed of 116 amino acids and is produced by the parafol-
licular cells (C cells) of the thyroid and by the neuroendocrine
cells of the lung and the intestine [3]. The level of procalcitonin
raises in a response to a proinﬂammatory stimulus, especially
of bacterial origin. The investigations identiﬁed PCT as part
of the complex pro-inﬂammatory response of the innate
immune system. In vitro stimulation of macrophages with
either bacteria or endotoxin results in rapid synthesis and
release of tumor necrosis factor, (TNF), interleukin (IL) -1,
and IL-6 [4]. Serum PCT serum levels are detectable as early
as 3–4 h after the invasion, which is much earlier than the
increase in the C-reactive protein level or erythrocyte sedimen-
tation rate [5,6]. Thus far, elevated PCT levels have not been
noted for other inﬂammatory conditions, such as inﬂamma-
tory bowel disease, temporal giant cell arteritis, polyarteritis
nodosa, systemic lupus erythematosus, gout, and Still disease
[7–10]. Available data indicate that PCT levels are not
inﬂuenced by therapy with glucocorticoids or nonsteroidal
anti-inﬂammatory agents [11,12]. PCT levels do not increase
or increase only modestly in patients with infection due to
respiratory viruses [13,14].Aim of the work
The aim of this work is to clarify the role of the serum procal-
citonin in predicting the bacterial exacerbations of COPD
patients and their needs for mechanical ventilation.Subjects and methods
This study was conducted at our university hospitals. A con-
sent was taken from each included subject. The study included
3 groups of subjects (Table 1):
Group 1: It included 30 bacteriologically conﬁrmed exacer-
bated COPD that admitted in the hospital. The mean age was
60.52 ± 11.07. There were 21 (70%) males and 9 (30%) females.
Group 2: It included 23 stable COPD under follow up at
outpatient department. The mean age was 58.60 ± 10.44.
There were 15 (65.22%) males and 8 (34.78%) females.Group 3: It included 20 healthy control subjects. The mean
age was 58.35 ± 9.25. There were 13 (65%) males and 7 (35%)
females.
The three groups were matched for age and sex (p value
>0.05).
The subjects included in this study had undergone the
following:
(1) Complete history taking and physical examination.
(2) Chest x ray examination.
(3) Complete blood picture (CBC).
(4) C reactive protein (CRP).
(5) Arterial blood gas analysis (ABGs).
(6) Bacteriological diagnostic tests for sputum, tracheo-
bronchial secretions and blood for exacerbating COPD
patients only. Serum antibodies titers (a 4-fold or more
increase in paired sera titers or a single titer greater than
or equal to 1:32) supported the diagnosis of mycoplasma
and chlamydial infections.
(7) Measurement of procalcitonin: This was done in all sub-
jects included in this study. Blood samples were taken
and the sera were separated and stored at 80 C for
further procalcitonin analysis. Procalcitonin levels were
determined with the commercially available automated
immunochemistry method (Brahms Kryptor, Brahms
Liaison, Berlin, Germany) [15].
Exclusion criteria
Any patient having any one of the following was excluded
from this study: (1) history of recent antibiotic therapy before
admission, (2) Evidence of pneumonia on chest radiograph; (3)
Evidence of bacterial infection elsewhere; (4) Immuno-
suppression; (5) Negative bacteriological diagnostic tests.
The diagnosis of COPD was established by clinical
symptoms, physical examination, chest radiography and pul-
monary function tests according to the guidelines of GOLD
[1]. The COPD subjects were classiﬁed into (stages I–IV) on
the basis of their post-bronchodilator forced expiratory
volume in one second (FEV1)/forced vital capacity (FVC)
and FEV 1% predicted. FEV1/FVC was <70% and their
FEV1 fell into set bands (stage 1: FEV1P 80%; stage 2:
50%P FEV1 < 80%; stage 3: 30%P FEV1 < 50%; stage
4: FEV1 < 30%).
Stable chronic obstructive pulmonary disease
Stable COPD is deﬁned by the absence of any exacerbation for
3 months preceding the study [16].
Acute exacerbation of COPD (AECOPD)
The American Thoracic Society (ATS) and European
Respiratory Society (ERS) deﬁne an exacerbation as an acute
change in a patient’s baseline dyspnea, cough, or sputum that
is beyond normal variability, and that is sufﬁcient to warrant a
change in therapy [17]. AECOPD was considered bacteriolog-
ically conﬁrmed in the presence of a positive Gram stain of res-
piratory samples, a pathogen concentration greater than
105 cfu/ml in tracheobronchial aspirations, a blood culture,
Table 2 Comparison between different subject groups regard-
ing PCT levels (ng/ml).
Groups PCT Mean ± SD
(ng/ml)
p Value
1. AECOPD patients 1.44 ± 0.542 1 vs 2 < 0.01
2. Sable COPD patients 0.05 ± 0.012 1 vs 3 < 0.01
3. Control subjects 0.04 ± 0.010 2 vs 3 > 0.05
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monary focus, or positive serological tests [18].
Statistical analysis
Statistical analysis was performed with the Statistical Package
for the Social Sciences, version 16 for Windows (SPSS Inc.,
Chicago, IL, USA). Values of p< 0.05 were considered statis-
tically signiﬁcant.
Results
There was a highly statistically signiﬁcant difference (p value
<0.001) between AECOPD patients on one side and stable
COPD patients and healthy control subjects on the other side
regarding the mean values of PCT (1.44 ± 0.542 ng/ml among
AECOPD patients, 0.05 ± 0.012 ng/ml among stable COPD
patients, 0.04 ± 010 ng/ml among healthy control subjects)
(Table 2 and Fig. 1). No statistically signiﬁcant difference (p
value >0.05) in the mean values of PCT was present among
non stable COPD patients and healthy control subjects
(0.05 ± 0.012 ng/ml among stable COPD patients, 0.04 ±
010 ng/ml among healthy control subjects) (Table 2 and Fig. 1).
The causative microbes among AECOPD patients were
shown in Table 3. Gram negative bacteria caused exacerbation
in 66.33% of the patients, Gram positive bacteria in 23.33% of
them and atypical bacteria in 13.34% of the patients.
Haemophilus inﬂuenzae (30%) was the most common organism
followed by Streptococcus pneumoniae (23.33%), Pseudomonas
aeruginosa (23.33%), Moraxella catarrhalis (10%),
Mycoplasma pneumoniae (6.67% and Chlamydia pneumoniae
(6.67%).
This study found a statistically signiﬁcant difference (p
value <0.05) between AECOPD patients infected with P.
aeruginosa and AECOPD patients infected with other bacteria
regarding the mean serum levels of PCT (Table 4). The cutoff
value of 1.215 ng/ml PCT serum level has 66.7% sensitivity
and 100% speciﬁcity for P. aeruginosa. The area under the
curve was 0.836 (Fig. 2).Table 1 Some characteristic data for the subjects included in this s
Exacerbated COPD (N= 30)
Age (Mean ± SD) 60.52 ± 11.07
Sex (Male/Female) 21/9
FEV1% 50.42 ± 19.5
FVC% 55.80 ± 17.9
FEV1/FVC% 55.3 ± 8.4
CRP (mg/L) 66.03 ± 22.85
WBC (·103/lL) 13.94 ± 4.20
PO2 59.3 ± 14.7
PCO2 42.2 ± 11.5
Smoking history
Current 8
Ex smoker 20
Non smoker 2
Severity of COPD by GOLD criteria
I (FEV1P 80% of predicted) 4 (13.33%)
I I (FEV1P 50% &< 80%) 7 (23.33%)
I I I (FEV1P 30% &< 50%) 11 (36.67%)
IV(FEV1 < 30% of predicted) 8 (26.67%)In this work 7 AECOPD patients required ventilator sup-
port. All these patients weaned successfully. None of these
patients died. A statistically signiﬁcant difference (p value
<0.001) was present among AECOPD patients that needed
ventilatory support (2.024 ± 0.564 ng/ml) and those did not
need mechanical ventilation (1.262 ± 0.399 ng/ml) (Table 5
and Fig. 3). At cutoff 1.495 ng/ml, PCT had 85.7% sensitivity
and 78.3% speciﬁcity for predicting AECOPD patients that
needed ventilatory support. The area under the curve was
0.891 (Fig. 4).
We detected a highly statistically positive correlation (p
value <0.001) between PCT serum levels, CRP (r= 0.662)
and WBC count (r= o.591). Also, we found a highly statisti-
cally negative correlation (p< 0.05) between PCT serum levels
and FEV1 (r= 0.625).
Discussion
In our study, there was a highly statistically signiﬁcant differ-
ence (p value <0.001) between AECOPD patients on one side
and stable COPD patients and healthy control subjects on the
other side regarding the mean values of PCT (1.44 ±
0.542 ng/ml among AECOPD patients, 0.05 ± 0.012 ng/ml
among stable COPD patients, 0.04 ± 010 ng/ml among
healthy control subjects). Other investigators found similar
results. In a study by Tasci et al. [19] the mean serum PCT
levels in COPD patients with exacerbations were 1.8 ng/ml
and in stable COPD patients was 0.2 ng/ml. A signiﬁcant cor-
relation was established between serum procalcitonin (PCT)tudy.
Stable COPD (N= 23) Healthy Subjects (N= 20)
58.60 ± 10.44 58.35 ± 9.25
15/8 13/7
55.98 ± 22.15 105 ± 9.22
60 ± 20.62 98 ± 11.50
59.3 ± 7.8 90 ± 7.83
6.43 ± 1.60 5.98 ± 1.44
7.6 ± 2.45 6.5 ± 2.74
63.51 ± 16.22 95.68 ± 2.9
40.01 ± 8.50 39.50 ± 2.66
6 0
14 0
3 20
5 (21.73%) –
8 (34.78%) –
7 (30.43%) –
3 (13.04%) –
Figure 1 Comparison between different subject groups regarding PCT levels (ng/ml).
Table 3 Microbiological proﬁle among AECOPD patients.
Bacteria type Microbes AECOPD patients no.
(%)
Gram +ve
(23.33%)
Streptococcus
pneumoniae
7 (23.33%)
Gram ve
(66.33%)
Haemophilus
inﬂuenzae
9 (30%)
Pseudomonas
aeruginosa
7 (23.33%)
Moraxella catarrhalis 3 (10%)
Atypical
(13.34%)
Mycoplasma
pneumoniae
2 (6.67%)
Chlamydia
pneumoniae
2 (6.67%)
Table 4 Comparison between different bacteria regarding
PCT levels (ng/ml).
Microbes PCT (ng/ml)
Mean ± SD
p Value
Pseudomonas
aeruginosa*
1.976 ± 0.623 *VS**
p< 0.05
Streptococcus
pneumoniae**
1.245 ± 0.416
Haemophilus inﬂuenzae** 1.198 ± 0.238
Moraxella catarrhalis** 1.166 ± 0.305
Mycoplasma
pneumoniae**
1.150 ± 0.071
Chlamydia pneumoniae** 1.250 ± .353
Figure 2 ROC curve for PCT serum levels among AECOPD
patients infected with Pseudomonas aeruginosa.
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lence (p= 0.002, p= 0.007 respectively). Mohamed and his
colleagues [20] found the levels of PCT for patients of group
A (bacterial exacerbated COPD) (2.69 ± 0.62 ng/ml) were sig-
niﬁcantly higher than group B (non bacterial exacerbated
COPD) (0.07 ± 0.02 ng/ml) and control group (0.05 ±
0.02 ng/ml) (p< 0.001). Pazarli et al. [21] analyzed PCT levels
among two selected COPD groups, AECOPD (the case group)
compared to stable COPD as a control group. This study dis-
covered that mean levels of PCT in AECOPD weresigniﬁcantly higher than COPD in stable conditions. In a study
by Zhang Y and his colleague [22], before treatment, the levels
of CRP, PCT, WBC, and N in the infective COPD group were
signiﬁcantly higher than that in the non-infective group
(p< 0.05 or p< 0.01), while there was no signiﬁcant differ-
ence in ESR level between the 2 groups (p> 0.05). In the
infective group, the levels of CRP, PCT, WBC, N and ESR
after the treatment were much lower than those before treat-
ment (p< 0.05). After treatment, the levels of CRP, PCT,
WBC, and neutrophils in the infective group were signiﬁcantly
Table 5 Comparison between mechanically ventilated and
non-mechanically ventilated AECOPD patients regarding PCT
serum levels (ng/ml).
COPD patients PCT
(Mean ± SD)
p Value
Mechanically ventilated (No = 7) 2.024 ± 0.564 p< 0.001
Non mechanically ventilated
(No = 23)
1.262 ± 0.399
Value of serum procalcitonin among exacerbated COPD patients 825higher compared with that in the non-infective group
(p< 0.05), while there was no signiﬁcant difference of ESR
level between the 2 groups (p> 0.05). There was a positive
relationship between PCT and CRP, ESR and WBC
(r= 0.46, 0.38, 0.20; p< 0.05), CRP and WBC as well as N
and ESR (r= 0.56, 0.43, 0.30; p< 0.05). Tanrıverdi et al.
[23] found that the mean PCT levels were signiﬁcantly higher
in COPD patients with positive sputum cultures than in
patients with negative sputum cultures. The cut-off values
for PCT, CRP, and the neutrophils/lymphocytes (N/L) ratio
for predicting a bacterial infection were 0.40 ng/mL,
91.50 mg/L, and 11.5, respectively; sensitivity was 61, 54, and
61% respectively; speciﬁcity was 67, 52, and 58%, respectively;
and the area under the curve (AUC) values were 0.64, 0.52,
and 0.58, respectively. The AUC value of PCT was signiﬁ-
cantly better for predicting bacterial infection compared with
the CRP level or the N/L ratio (p= 0.042). The investigations
identiﬁed PCT as part of the complex pro-inﬂammatory
response of the innate immune system. In vitro stimulation
of macrophages with either bacteria or endotoxin results in
rapid synthesis and release of tumor necrosis factor, (TNF),
interleukin (IL) -1, and IL-6 [4]. Within 4 h, the synthesis of
PCT is detectable. PCT differs from other biomarkers of the
invasion by bacterial pathogens. Serum PCT serum levels are
detectable as early as 3–4 h after the invasion, which is much
earlier than the increase in the C-reactive protein level or ery-
throcyte sedimentation rate [5,6].
In this study, we found Gram negative bacteria caused
COPD exacerbation in 66.33% of the patients, Gram positive
bacteria in 23.33% of them and atypical bacteria in 13.34% ofFigure 3 Comparison between mechanically ventilated and non-mech
(ng/ml).the patients. H. inﬂuenzae (30%) was the most common organ-
ism followed by S. pneumoniae (23.33%), P. aeruginosa
(23.33%), M. catarrhalis (10%), M. pneumoniae (6.67% and
C. pneumoniae (6.67%). Similar results detected by the others.
In a study by Soler et al. [18] the microbial patterns among
COPD exacerbation corresponded to community-acquired
pathogens (S. pneumoniae, H. inﬂuenzae, and moraxella catar-
rhalis) in 19 of 34 (56%) and to Gram-negative enteric bacilli
(GNEB), pseudomonas, and Stenotrophomonas spp. in 15 of
34 (44%) of isolates. C. pneumoniae and respiratory viruses
were found in 18% and 16% of investigations, respectively.
Ko and his group [24] found among sputum samples from
the 530 episodes of AECOPD hospital admissions, a positive
growth of H. inﬂuenzae, P. aeruginosa, and S. pneumoniae.
In a study by Nakou et al. [25] conducted on the exacerbated
COPD patients, the most common bacteria were H. inﬂuenzae
and P. aeruginosa (23.9 and 14.1%, respectively).
Acinetobacter baumannii- and P. aeruginosa-positive cultures
were associated with prolonged hospitalization and severe air-
way obstruction (p= 0.03 and 0.031, respectively). C. pneumo-
niae orM. pneumoniae infection was diagnosed in four and two
patients, respectively.
This study found a statistical signiﬁcant difference (p value
<0.05) between AECOPD patients infected with P. aeruginosa
and AECOPD patients infected with other bacteria regarding
the mean serum levels of PCT. The cutoff value of 1.215 ng/ml
PCT serum level has 66.7% sensitivity and 100% speciﬁcity for
P. aeruginosa. The area under the curve was 0.836. Our ﬁnd-
ings agree with other investigators. Daubin and his group
[26] detected high PCT serum levels among COPD patients
with P. aeruginosa. These results are expected due to the viru-
lence of P. aeruginosa and the associated exuberant inﬂamma-
tory reactions.
A statistically signiﬁcant difference (p value <0.001) was
present among AECOPD patients that needed ventilatory sup-
port and those did not need, At cutoff 1.495 ng/ml, PCT had
85.7% sensitivity and 78.3% speciﬁcity for predicting
AECOPD patients that needed ventilatory support. The area
under the curve was 0.891. Other researchers discovered simi-
lar results. Rammaert et al. [27] revealed that higher PCT levels
in severe AECOPD cases were associated with the necessity of
mechanical ventilation and intensive care unit mortality. In theanically ventilated AECOPD patients regarding PCT serum levels
Figure 4 ROC curve for PCT serum levels among AECOPD
patients that mechanically ventilated.
826 A.A. El Halim, M. Sayedsame study they reported high mortality rate in cases whose
PCT levels were higher than 0.24 ng/ml. In a study by
Pazarli et al. [21] the mean PCT levels increased, especially
in cases with severe AECOPD and those receiving NPPV
among them. They determined a cutoff value of PCT as
0.10 ng/ml as a predictor of the necessity of non invasive
positive pressure ventilation (NPPV) in AECOPD.
We detected a highly statistically positive correlation (p
value <0.001) between PCT serum levels, CRP (r= 0.662)
and WBC count (r= 0.591). Also, we found a highly statisti-
cally negative correlation (p< 0.05) between PCT serum levels
and FEV1 (r= 0.625). These results agreed with that of
other studies. Pazarli and his colleagues [21] detected a signif-
icant positive correlation between PCT levels during COPD
exacerbation, and CRP, ESR, WBC and neutrophil counts.
Also, Daniels et al. [28] reported positive correlation between
PCT and CRP. Mohamed et al. [20] found that PCT has a sig-
niﬁcant correlation with both ESR, CRP, leucocytes count and
body temperature. Also in this study, a high PCT pointed to
increasing severity of AECOPD. Daubin et al. [26] reported
PCT levels of >0.25 l/L in patients with very severe COPD.
Rammaert et al. [27] revealed that higher PCT levels in severe
AECOPD cases were associated with the necessity of mechan-
ical ventilation and intensive care unit mortality.
Conclusions
This study found increased PCT serum levels among
AECOPD patients and suggests a role for PCT in the predict-
ing of bacterial infections and their needs for ventilatory sup-
port. We recommend other large studies to augment our
ﬁndings.Conﬂict of interest
We have no conﬂict of interest to declare.
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